Clinicopathological Properties of Non-Hodgkin Lymphomas in the South-West of Turkey
Cancer Research Journal
Volume 1, Issue 2, July 2013, Pages: 15-19
Received: Jun. 27, 2013;
Published: Aug. 10, 2013
Views 3259 Downloads 162
Erdal Kurtoğlu, Antalya Education and Research Hospital, Department of Hematology, Antalya, Turkey
Mustafa Yıldırım, Ministry of Health Batman Regional Government Hospital, Department of Medical Oncology, Batman, Turkey
Hülya Karakılınç, Antalya Provincial Health Directorate, Cancer Registration Center, Antalya, Turkey
Mustafa Yıldız, Antalya Education and Research Hospital, Department of Medical Oncology, Antalya, Turkey
Sevil Göktaş, Antalya Education and Research Hospital, Department of Medical Oncology, Antalya, Turkey
Dinç Süren, Antalya Education and Research Hospital, Department of Pathology, Antalya, Turkey
Vildan Kaya, Süleyman Demirel University School of Medicine, Department of Radiation Oncology, Isparta
Objective: Non-Hodgkin Lymphomas, which have numerous histological subgroups, entail various biological behaviour, clinical properties and epidemiological differences. Incidence of histological subtypes can vary according to geographical locations. In this article, we will discuss clinicopathological properties of Non-Hodgkin Lymphoma patients in Antalya, which is located in the south-west of Turkey. Material and Method: This study used the data from 1994 to 2010 on the patients from the data bank of Turkish Ministry of Health, Antalya Provincial Health Directorate, Cancer Registration Center. Results: The study covered a total of 1521 patients, including 899 (59.1%) male and 622 (40.9%) female patients. One-hundred thirty (8.6%) of the patients were under the age of 20, 911 (60%) were aged between 20-65, and 477 (31.4%) were above the age of 65. Cellular origins of Non-Hodgkin Lymphomas were evaluated in 1518 patients. B-cell originated Non-Hodgkin Lymphoma was identified as the most common with 86.4% (Table 1). We also revealed that T-cell originated Non-Hodgkin Lymphomas were more common under the age of 20. Conclusions: Clinicopathologic properties of Non-Hodgkin Lymphomas vary across countries as well as across regions in a country. We believe that such differences should be taken into account in the diagnosis and treatment of these patients.
Clinicopathological Properties of Non-Hodgkin Lymphomas in the South-West of Turkey, Cancer Research Journal.
Vol. 1, No. 2,
2013, pp. 15-19.
Eser S, Yakut C, Özdemir R, et al. Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev 2010; 11: 1731-9.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 27: 2893-7.
Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 2004; 13: 138-43.
Altekruse SF KC, Krapcho M, Neyman N, eds. Cancer Statistics Review 2007; 1975-2007.
Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol 2000; 11: 63-7.
Anderson JR, Armitage JO, Weisenburger DD.Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717-20.
Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
Isikdogan A, Ayyildiz O, Buyukcelik A, et al. Non-Hodgkin's lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol 2004; 83: 265-9.
Barista I, Tekuzman G, Firat D, et al. Non-Hodgkin's lymphomas in Turkey:eighteen years' experience at the Hacettepe University. Jpn J Cancer Res 1994; 85: 1200-7.
Sarpel SC, Paydas S, Tuncer I, Varinli S, Koksal M, Akoglu T. Non-Hodgkin's lymphomas in Turkey. Cancer 1988; 62: 1653-7.
Alici S, Bavbek SE, Kaytan E, Başaran M, Eralp Y, Onat H (2002). Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors. Am J Clin Oncol, 25, 502-8.
Armitage JO (1997). A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, 3909-18.
Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 2007; 7: 166-75.
Sant M, Allemani C, Tereanu C, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-34.
Shih LY, Liang DC. Non-Hodgkin’s lymphomas in Asia. Hematol Oncol Clin North Am 1991; 5: 983–01.
Ho FC, Todd D, Loke SL, Ng RP, Khoo RK. Clinicopathologic features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period. Int J Cancer 1984; 34: 143–8.
Piccaluga PP, Sapienza MR, Agostinelli C, et al. Biology and treatment of follicular lymphoma. Expert Rev Hematol 2009; 2: 533-47.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30: 802-10.
Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma:recent findings regarding an emerging epidemic. Ann Oncol 1994; 5: 9-24.
Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillanceseries: non-Hodgkin’s lymphoma incidence by histologicsubtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92:1240-51.
Devesa SS, Fears T Non-Hodgkin’s lymphoma time trends:United States and international data. Cancer Res 1992; 52: 5432s-40s.
Hartge P, Devesa SS, Fraumeni Jr JF. Hodgkin’s and non-Hodgkin’s lymphomas. Cancer Surv 1994; 20: 423-53.
Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2002; 241-62.
Zucca E, Cavalli F Extranodal lymphomas. Ann Oncol 2000; 11: 219-22.
Doglioni C, Wotherspoon AC, Moschini A, de Boni M, Isaacson PG.. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339: 834.
Arican A, Dinçol D, Akbulut H, et al. Clinicopathologic features and prognostic factors of primary extranodal non-Hodgkin's lymphomas in Turkey. Am J Clin Oncol 1999; 22: 587-592.
Eser B, Kaplan B, Unal A, et al Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas in central Anatolia, in Turkey. Yonsei Med J 2006; 47: 22-33.
Erkurt MA, Aydogdu I, Kuku I, Kaya E, Basaran Y. Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas: 10 years of experience from a single center in eastern Anatolia. Med Princ Pract 2009; 18: 399-406.
Dinçol D, Içli F, Erekul S, et al. Primary gastrointestinal lymphomas in Turkey: a retrospective analysis of clinical features and results of treatment. J Surg Oncol 1992; 51: 270-273.
Paydas S, Kekec Y, Zorludemir S. Gastrointestinal lymphoma in southern Turkey. Cent Afr J Med 1996; 42: 56–60.